文献速递妇科

妇科恶性肿瘤肠梗阻谱系与Henry评分应用研究

Understanding the spectrum of malignant bowel obstructions in gynecologic cancers and the application of the Henry score.
PubMed 文献 · Gynecol Oncol · 2023-05-12

回顾性分析2016至2021年单中心收治的179例妇科恶性肿瘤合并恶性肠梗阻患者共269次入院,89.4%非手术治疗、10.6%手术治疗,两种管理方式生存无显著差异;Henry评分升高与30天死亡率升高相关(0-1分0%、2-3分14.3%、4-5分40.9%),全队列1个月和6个月死亡率分别为20.1%和60.9%。

要点

  • 妇科恶性肿瘤合并恶性肠梗阻患者中位卵巢癌最常见,多数(89.4%)非手术治疗。
  • Henry评分0-1、2-3、4-5分对应30天死亡率分别为0%、14.3%、40.9%。
  • 34.1%患者因复发或持续性恶性肠梗阻再次入院,6个月死亡率达60.9%。

核心结论

  • 妇科恶性肿瘤患者初始恶性肠梗阻入院后生存率差。
  • Henry评分可用于评估妇科恶性肿瘤患者的30天死亡率,可能有助于管理和咨询。

研究设计与样本

  • 回顾性研究,纳入2016至2021年单中心收治的妇科恶性肿瘤合并恶性肠梗阻患者179例,共269次入院。

主要发现

  • 179例患者共269次入院,最常影响卵巢癌患者。
  • 89.4%非手术治疗,10.6%手术治疗,两种管理方式生存无显著差异。
  • 30天死亡率随Henry评分升高而增加:0-1分为0%,2-3分为14.3%,4-5分为40.9%。
  • 34.1%患者因复发或持续性恶性肠梗阻再次入院。
  • Henry评分4-5分患者中56.8%记录了照护目标讨论;全队列1个月和6个月死亡率分别为20.1%和60.9%。

临床怎么用

  • 作者认为Henry评分可用于评估妇科恶性肿瘤合并恶性肠梗阻患者的30天死亡率,并可能有助于管理和咨询。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Malignancy-associated bowel obstruction (MBO) is a potential sequela of advanced gynecologic cancers, adversely impacting both quality of life and prognosis. The Henry score (HS) was developed in a gastrointestinal cancer-predominant population to predict 30-day mortality. We aim to characterize MBO in gynecologic cancers and assess the utility of the HS in this population. METHODS: This is a retrospective review of patients with gynecologic cancer and MBO admitted to a single academic institution from 2016 to 2021. The primary outcome is to characterize malignant small and large bowel obstructions in primary and recurrent gynecologic cancer using readmission and mortality rates. Secondary outcomes are to assess the Henry score and inpatient MBO management. RESULTS: 179 patients totaling 269 were admissions identified, most commonly affecting patients with ovarian cancer. The majority (89.4%) were managed non-operatively while 10.6% were managed surgically. No significant differences were observed in survival for medical versus surgical management. Thirty-day mortality increased with increasing HS (0%, 0-1; 14.3%, 2-3; 40.9%, 4-5). Over 1/3 (34.1%) of patients were readmitted for recurrent or persistent MBO. Goals of care conversations were documented for 56.8% of patients with HS 4-5. Mortality rates across the entire cohort were high-20.1% and 60.9% had died by 1 and 6 months, respectively. CONCLUSIONS: Survival rates following an initial MBO admission are poor. The HS has utility in gynecologic cancers for assessing 30-day mortality and may be a useful tool to aid in the management and counseling of patients with gynecologic cancer and MBO.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Moyett JM, Howell EP, Broadwater G, et al. Understanding the spectrum of malignant bowel obstructions in gynecologic cancers and the application of the Henry score. Gynecol Oncol. 2023. PMID: 37182431. doi:10.1016/j.ygyno.2023.04.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。